Related Experiment Video

Updated: May 20, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Combining structural brain changes improves the prediction of Alzheimer's disease and mild cognitive impairment

Ningnannan Zhang1, Xiaowei Song, Yunting Zhang

  • 1National Research Council Canada Institute for Biodiagnostics (Atlantic), Halifax, N.S., Canada.

Dementia and Geriatric Cognitive Disorders
|July 5, 2012
PubMed
Abstract

Insights

Combining medial temporal lobe atrophy (MTA) with other brain changes improves Alzheimer's disease (AD) prediction. This approach enhances diagnostic accuracy and monitoring for AD progression.

Area of Science:

  • Neuroimaging
  • Alzheimer's Disease Research
  • Biomarker Discovery

Background:

  • Alzheimer's disease (AD) is characterized by distinct structural brain alterations.
  • Medial temporal lobe atrophy (MTA) is a key indicator of AD.
  • This study aimed to enhance AD prediction by integrating MTA with other brain changes.

Purpose of the Study:

  • To evaluate the predictive performance of MTA and a composite brain atrophy and lesion index (BALI) for Alzheimer's disease.
  • To assess the additive effect of combining MTA and BALI for predicting AD.
  • To explore the utility of these markers in diagnosing AD and monitoring its progression.

Main Methods:

  • High-resolution MRI scans from individuals with mild AD, mild cognitive impairment (MCI), and healthy controls (HC) were analyzed.
  • Medial temporal lobe atrophy (MTA) was quantified using the medial temporal lobe atrophy scale (MTAS).
  • A brain atrophy and lesion index (BALI) was used to summarize other common brain changes. Logistic regression models assessed predictive performance.

Main Results:

  • Both MTAS and BALI scores differed significantly between diagnostic groups and were correlated.
  • An unfavorable MTAS score independently predicted MCI to AD conversion (OR = 3.71, p = 0.039).
  • Combining MTAS and BALI significantly improved predictive accuracy for AD (OR = 8.99, p = 0.007; 75.9% accuracy).

Conclusions:

  • Structural brain changes in AD have an additive effect on disease progression.
  • Combining MTA with other brain atrophy markers enhances diagnostic capabilities for AD.
  • This combined approach shows promise for AD diagnosis, monitoring disease progression, and evaluating treatment efficacy.

More Related Videos

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...